Bone homeostasis is maintained by the balance between the bone-forming activity of osteoblasts and the bone-resorbing activity of osteoclasts.1) Excessive osteoclastic bone resorption results in bone destructive disorders such as osteoporosis. Osteoclasts are multinucleated cells that differentiate from hematopoietic precursors and are capable of resorbing mineralized bone.2) Receptor activator of nuclear factorkappa B (NF-kB) ligand (RANKL), a member of the tumor necrosis factor (TNF) family produced by osteoblasts and stromal cells, is an essential factor for osteoclast differentiation and function.3,4) Tartrate-resistant acid phosphatase (TRAP) is a marker enzyme for osteoclasts. RANKL induces the formation of TRAP-positive multinucleated cells (TRAP ϩ MNCs) in cultures of bone marrow cells (BMCs) in the presence of macrophage colony-stimulating factor (M-CSF) without requiring osteoblasts or stromal cells. 5,6) RAW264 cells are also known to differentiate into osteoclasts in the presence of RANKL. 5,7,8) Compounds that inhibit osteoclast differentiation and/or function are useful for treating or preventing bone diseases characterized by excessive bone resorption.We screened various compounds of natural origin for their abilities to affect osteoclast differentiation, and identified honokiol as a promising candidate. Honokiol, a neolignan, is an active ingredient of kouboku (stem bark of Magnolia obovata), an herb used in traditional Chinese medicine.
9)It is known to have many physiological activities, including anti-inflammatory, anti-allergic, anti-platelet, and anti-tumor properties.10-15) However, the effects of honokiol on osteoclastic bone resorption processes have not previously been investigated in detail. In the present study, we evaluated the effects of honokiol on osteoclast differentiation, function and survival, and determined a possible mechanism of action. Agriculture and Technology; Fuchu,
MATERIALS AND METHODS
Reagents
Honokiol Inhibits Osteoclast Differentiation and Function in Vitro